Australia's largest stock trading and investment forum Australia's #1 stock forum

BNO

Click for more information

0.00%

1.0¢ bionomics limited

Ann: Follow-up Analysis from PREVAIL Phase 2 Study of BNC210 in S, page-11

First 11 Last

Share
Profile

Follow
1lluminator

2,097 Posts.

346

09/03/23

21:23

Post #: 66687010
Share

Originally posted by doubledeckerdog: ↑

They will burn half the cash and the rest will be paid out in ridiculous salaries and bonuses.

For those of a charting orientation, the stock is already in overbought territory / but the muppets and naive will probably chase it a bit more before the execs start selling into the strength.

And I’d check your numbers, as I’d be surprised if half the valuation is cash - but just because it is, does not imply that the IP is of equivalent value - because until it passes Phase III clinical trials AND is approved by FDA, it’s basically not worth a razoo!

DDD

Expand

so you're saying all biotech's are worth zero unless they're fda approved?

that doesn't make sense to me but everyone's got their own investment criteria.

thanks for the reply anyway.
1 Upvote

0 Great analysis

Reply

Top Stories

PTR

Petratherm adds $1.6 to the piggybank ahead of SA titanium drilling program

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

WR1

Winsome scoping study proposes low-cost operation for Adina lithium project

WMG

Western Mines identifies 2 high-grade zones at Mulga Tank in WA

ALR

Altair Minerals hits high-grade copper and gold at Wee MacGregor, QLD

There are more pages in this discussion • 22 more messages in this thread...

First 11 Last

Add BNO (ASX) to my watchlist